Skip to content

    Biocon

    BIOCON
    Healthcare·9 May 2025
    Management Summary

    Biocon reported a robust Q4 FY25 with 15% like-for-like revenue growth, driven by strong performance across Generics, Biosimilars, and Research Services. The quarter saw key product launches and approvals, including Yesintek™ in the U.S. and Liraglutide in the U.K., alongside strategic acquisitions by Syngene. While full-year Generics EBITDA was impacted by pricing pressure and new plant costs, the company is positioned for accelerated growth with new product launches and capacity expansions.

    Highlights

    5
    • Group Revenue from operations reached INR 4,417 crores, reflecting a solid 15% year-on-year increase on a like-for-like basis and a 16% sequential growth.

    • Group Core EBITDA for the quarter stood at INR 1,363 crores, a 16% increase from last year with a healthy core operating margin of 31%.

    • Generics business reported Q4 Revenue from Operations of INR 1,048 crores, up 46% year-on-year and 53% sequentially, driven largely by the sale of launch quantities of Lenalidomide.

    • Biosimilars revenue for Q4 was INR 2,463 crores, which is a 9% year-on-year increase on a like-for-like basis, translating into an EBITDA of INR 540 crores, representing a healthy 22% margin.

    • Syngene ended Q4 with Revenue from Operations of INR 1,018 crores, an 11% year-on-year increase, crossing the INR 1,000 crore threshold for the first time with a 35% EBITDA margin.

    Concerns

    3
    • FY25 Generics EBITDA was INR 377 crores with a margin of 12%, reflecting pricing pressure and higher operational expenditure linked to new plant capitalizations.

    • FY25 Biosimilars EBITDA, excluding the one-time gain from the BFI business divestment, was INR 1,971 crores with a margin of 22%, which is lower than the reported EBITDA of INR 3,028 crores.

    • Revenues from generic Revlimid are expected to be lumpy before the market opens up in January 2026 for unlimited volume launch by all generic companies.

    What Changed2

    vs Q1 FY26

    Guidance items13 → 17 (+4)Risks discussed5 → 4 (-1)
    Key financials

    Metrics

    5

    Periods

    2

    Q4

    3
    • Revenue from Operations
      ₹4,417 Cr
      YoY+15%QoQ+16%
    • Core EBITDA
      ₹1,363 Cr
      YoY+16%
    • Core Operating Margin
      31%

    FY25

    2
    • Revenue from Operations
      ₹15,262 Cr
      YoY+10%
    • Reported Net Profit
      ₹1,013 Cr

    Segment breakdown

    • Generics₹243 Cr21.2%
    • Biosimilars₹540 Cr47.1%
    • Syngene₹363 Cr31.7%
    Donut· Share of EBITDA (Q4)

    Capital allocation

    3
    high confidence
    CategoryHeadline
    Capex

    Capex disclosed

    Debt

    Net USD 1.1 billion

    M&A

    Biologics manufacturing facility

    acquisition · closed

    Guidance & targets

    17
    CategoryTargetPriority
    Generics
    Tacrolimus commercialization in China
    Q1 FY26
    High
    Generics
    Liraglutide Europe launch
    Q2 FY26
    High
    Generics
    Liraglutide U.S. target action date
    H2 calendar year
    High
    Generics
    Generic Revlimid unlimited volume launch
    Jan '26
    High
    Generics
    Capex next year
    USD 50 million
    High
    Biosimilars
    Bevacizumab U.S. launch
    H1 FY26
    High
    Biosimilars
    Aspart U.S. approval/launch
    H1 FY26
    High
    Biosimilars
    Aflibercept Canada launch
    July of this year
    High
    Biosimilars
    Aflibercept U.S. market entry
    no later than H2 2026
    High
    Biosimilars
    Denosumab EU approval
    in a couple of months
    High
    Biosimilars
    Denosumab FDA approval
    expected by the end of this year
    High
    Biosimilars
    New biosimilars launches
    5
    High
    Biosimilars
    Product launch frequency
    a product a year
    High
    Biosimilars
    R&D investment % of revenue
    7-9%
    High
    Biosimilars
    Capex over next couple of years
    USD 100 million
    High
    Capital Raise
    First tranche completion
    mid-June
    High
    Restructuring
    Update on committee recommendations
    in a few months
    High

    Capital Raise First Tranche Completion

    Mid-June
    CurrentIn progress, shareholders' notice sent
    TargetCompletion of first tranche

    Why it matters

    Crucial for meeting financial obligations related to structured debt and strengthening the balance sheet.

    We expect to complete the first tranche, which we will decide the quantum of that first tranche in a few weeks. But this first tranche is expected to be complete by middle of June.

    How to verify

    capital_allocation.debt.actions

    Risks & concerns

    4
    RiskSeverity

    Pricing pressure in Generics business

    FY25 Generics EBITDA margin of 12% reflected pricing pressure.Management acknowledged

    medium

    Higher operational expenditure from new plant capitalizations

    Impacted FY25 Generics EBITDA due to peptide API facility, Vizag fermentation, and U.S. Cranberry facility.Management acknowledged

    medium

    Lumpy revenues for generic Revlimid

    Revenues will be lumpy until January 2026 when unlimited volume launch is permitted.Management acknowledged

    medium

    Market volatility impacting strategic options

    Market volatility on the IPO front led the Board to evaluate other strategic options, including a merger of BL and BBL.Management acknowledged

    medium

    Q&A highlights

    7

    “We have over 70% market access with the payers in the U.S. at the beginning of the start. With that comes the opportunity for us to continue to pull the product through in the U.S. We are very bullish on our market share. ... The pricing situation remains stable. We're certainly in a good position.”

    Provides specific details on market access and management's confidence in market share growth and stable pricing for a key biosimilar launch.

    asked by Damayanti Kerai

    3 min read7 chapters

    Detailed Narrative

    01

    Robust Q4 Performance Across Segments

    Biocon delivered a strong Q4 FY25, with overall revenue from operations reaching INR 4,417 crores, marking a 15% year-over-year and 16% sequential growth on a like-for-like basis. This growth was broad-based, with Generics surging 46% YoY, Biosimilars growing 9% YoY, and Research Services (Syngene) expanding 11% YoY. The group's core EBITDA stood at INR 1,363 crores, a 16% increase YoY, achieving a healthy 31% operating margin.

    02

    Strategic Product Launches and Approvals

    The quarter was marked by significant advancements in Biocon's product portfolio. Key highlights included the global launch of Liraglutide in the U.K. and the introduction of Lenalidomide and Dasatinib in the U.S. Notably, Yesintek™ (biosimilar Ustekinumab) was successfully launched in the U.S., securing over 70% market access with payers and covering over 100 million lives, becoming the fifth product from Biocon's portfolio to enter the U.S. market.

    03

    Biosimilars Momentum and Pipeline

    Biocon Biologics demonstrated strong commercial momentum, with Fulphila® (Pegfilgrastim) and Ogivri® (Trastuzumab) achieving U.S. market shares of 30% and 26% respectively, a two-fold increase from the previous year. The company secured U.S. FDA approval for Jobevne™ (biosimilar Bevacizumab) and received a positive EU CHMP opinion for biosimilar Denosumab, with U.S. approval expected by year-end. The settlement with Regeneron secured a U.S. market entry for Yesafili™ (biosimilar Aflibercept) no later than H2 2026, with a Canada launch slated for July 2025.

    04

    Generics Business Growth and Future Drivers

    The Generics business recorded its strongest quarter in FY25, with revenue reaching INR 1,048 crores, driven primarily by the launch quantities of Lenalidomide. While FY25 Generics EBITDA margin was 12% due to pricing pressure and new plant capitalizations, future growth is expected from upcoming launches like Liraglutide in Europe (Q2 FY26) and the U.S. (H2 calendar year), as well as generic Copaxone and Everolimus in the U.S. Tacrolimus supplies to China commenced, with commercialization expected in Q1 FY26.

    05

    Capital Allocation and Funding Strategy

    Biocon announced plans to raise INR 4,500 crores through a combination of QIP and private placement, with the first tranche expected by mid-June. These proceeds will primarily be used to meet financial obligations related to structured debt for Biocon Biologics. The company's net debt stood at USD 1.1 billion (USD 1.2 billion normalized) as of March 31, 2025, with net inventory at USD 390 million and receivables around 90 days, indicating improved working capital management.

    06

    Strategic Review and GLP-1 Investments

    In response to market volatility🌐, the Board has constituted a committee to evaluate strategic options, including a possible merger of Biocon Limited and Biocon Biologics Limited, with an update expected in a few months. The company has also made significant investments in GLP-1s, capitalizing a large-scale drug substance capacity in FY25 and commissioning a new injectable facility in FY26, positioning itself to address the substantial market opportunity for drugs like Semaglutide (off-patent 2031) and Tirzepatide (after 2036).

    07

    Syngene's Expansion and Performance

    Syngene International achieved a milestone, with its Q4 revenue crossing INR 1,000 crores for the first time, reaching INR 1,018 crores, an 11% YoY increase. Its EBITDA for the quarter was INR 363 crores, with a 35% margin. The acquisition of a biologics manufacturing facility in the U.S. further enhances Syngene's capabilities in the global CRDO market and establishes its first U.S. manufacturing footprint.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.